Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Mallinckrodt
McKesson
Harvard Business School
Colorcon

Last Updated: August 19, 2022

Investigational Drug Information for VX-661


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug VX-661?

VX-661 is an investigational drug.

There have been 50 clinical trials for VX-661. The most recent clinical trial was a Phase 3 trial, which was initiated on May 24th 2017.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and [disabled in preview]. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, Cystic Fibrosis Foundation, and Cystic Fibrosis Trust.

There are ninety US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for VX-661
TitleSponsorPhase
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyVertex Pharmaceuticals IncorporatedPhase 3
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delVertex Pharmaceuticals IncorporatedPhase 3
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic ImpairmentVertex Pharmaceuticals IncorporatedPhase 1

See all VX-661 clinical trials

Clinical Trial Summary for VX-661

Top disease conditions for VX-661
Top clinical trial sponsors for VX-661

See all VX-661 clinical trials

US Patents for VX-661

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VX-661 See Plans and Pricing Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA) See Plans and Pricing
VX-661 See Plans and Pricing Modulators of ATP-binding cassette transporters Vertex Pharmaceuticals Incorporated (Boston, MA) See Plans and Pricing
VX-661 See Plans and Pricing Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof Vertex Pharmaceuticals Incorporated (Boston, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Mallinckrodt
McKesson
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.